Biotech is notoriously risky. The odds of a drug getting FDA approval are staggeringly low, and even then companies aren’t in the clear. Investors might just think biotech is just way too risky to bother with… but it doesn’t have to be.
In this week’s episode of Industry Focus: Healthcare, host Shannon Jones and Motley Fool contributor Brian Feroldi share three methods that can get you exposure to biotech-style gains without taking on so much of that going-to-zero-overnight risk. Listen in to hear the pros and cons to investing in sector-wide ETFs, contract research organizations, and picks and shovels plays -- plus, of course, some companies to add to your watchlist in each of those categories.
------------------------------------------------------------------------
Subscribe to The Motley Fool's KZfaq Channel:
/ themotleyfool
Or, follow our Google+ page:
plus.google.com/+MotleyFool/p...
Inside The Motley Fool: Check out our Culture Blog!
culture.fool.com
Join our Facebook community:
/ themotleyfool
Follow The Motley Fool on Twitter:
/ themotleyfool